MCM
NAVB

MAI Capital Management’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

MAI Capital Management’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-1,000
Closed -$53K – 366
2013
Q2 		$53K Buy
+1,000
New +$49.9K 0.01% 310

Other funds holding NAVB

PM
Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

MAI Capital Management's NAVB Position: Q3 2013 in Review

MAI Capital Management sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q3 2013, closing a stake of 1,000 shares — an estimated $53K sold.

MAI Capital Management first reported a position in NAVB in Q2 2013 and held it in 1 quarter. The position peaked at $53K in Q2 2013. 79 funds tracked by Wall St. Rank hold NAVB as of Q3 2013.

  • MAI Capital Management reported no remaining Navidea Biopharmaceuticals Inc. position as of Q3 2013 after selling out during the quarter.
  • MAI Capital Management sold 1,000 Navidea Biopharmaceuticals Inc. shares in Q3 2013, an estimated $53K.
  • MAI Capital Management first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 1 quarter.
  • MAI Capital Management's Navidea Biopharmaceuticals Inc. position peaked at $53K in Q2 2013.
  • 79 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2013.

Based on MAI Capital Management's 13F filing for Q3 2013, filed 28 Oct 2013.